Abrilada Shortage Update: What Patients Need to Know in 2026

If you've been having trouble getting your Abrilada (Adalimumab-afzb) prescription filled, you may be wondering: is there an actual shortage? The short answer is complicated. While Abrilada is not formally listed on the FDA Drug Shortage Database, many patients still experience difficulty accessing it due to the unique way specialty biologics are distributed and covered by insurance.

In this article, we'll break down the current state of Abrilada availability in 2026, explain why it can be hard to find, and give you actionable steps to get your medication.

Is Abrilada Still in Shortage?

As of early 2026, Abrilada is not listed as a shortage drug by the FDA or the American Society of Health-System Pharmacists (ASHP). Pfizer continues to manufacture and distribute Abrilada through specialty pharmacy channels.

However, the fact that it's not in "shortage" doesn't mean it's easy to find. Abrilada's availability depends heavily on:

• Which specialty pharmacy your insurance plan uses
• Whether Abrilada is the preferred adalimumab biosimilar on your formulary
• Your insurance plan's prior authorization requirements
• Regional distribution patterns

In other words, Abrilada is being manufactured — but whether you can actually get it depends on your specific insurance and pharmacy situation.

Why Is Abrilada Hard to Find?

Even without a formal shortage, several factors make Abrilada challenging for patients to access:

Specialty Pharmacy Distribution

Abrilada is a biologic medication that requires refrigeration and is dispensed exclusively through specialty pharmacies. Unlike standard prescriptions, you can't just walk into a retail pharmacy and pick it up. This adds time and complexity to the process.

Insurance Formulary Restrictions

The adalimumab biosimilar market is one of the most competitive in the pharmaceutical industry. Since 2023, ten biosimilars to Humira have entered the market. Insurance companies and PBMs negotiate aggressive deals with manufacturers, and each plan typically selects one or two "preferred" biosimilars. If Abrilada isn't your plan's preferred product, you may face coverage denials, higher copays, or mandatory switches to a different biosimilar.

Prior Authorization Delays

Almost all insurance plans require prior authorization for adalimumab products. This process involves your doctor submitting clinical documentation to justify the prescription. Delays in this process — sometimes lasting weeks — can leave patients without their medication.

The Crowded Market

With biosimilars from Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Hadlima), Sandoz (Hyrimoz), and others competing for market share, specialty pharmacies may stock only the biosimilars their largest clients prefer. Abrilada may simply not be the primary product at your designated specialty pharmacy.

How Much Does Abrilada Cost in 2026?

Abrilada's pricing follows a dual-WAC model:

• Standard list price: Approximately 5% below Humira's wholesale acquisition cost (WAC), which puts it around $6,500 to $7,000 per month at list price.
• Low WAC version: Approximately 60% below Humira's list price, or roughly $2,800 to $3,200 per month.

With a coupon from services like GoodRx, cash-paying patients may find Abrilada for around $2,050 to $3,530 per month.

For commercially insured patients, Pfizer's enCompass Co-Pay Assistance Program can reduce out-of-pocket costs to as low as $0 per month. If you're uninsured or underinsured, Pfizer's Patient Assistance Program (Pfizer RxPathways) may provide Abrilada at no cost.

For more pricing details and savings strategies, read our guide on how to save money on Abrilada in 2026.

New Options for Patients in 2026

The biosimilar landscape continues to evolve, and patients have more choices than ever. Here are some developments worth knowing about:

• More interchangeable biosimilars: As of early 2026, seven adalimumab biosimilars have FDA interchangeable designations, giving pharmacists more flexibility to substitute at the counter.
• Lower prices across the board: Competition has driven prices down significantly. Some biosimilars are now available at 85% below Humira's original list price.
• Improved patient support: Manufacturers including Pfizer have expanded their patient support programs with dedicated case managers, co-pay cards, and faster specialty pharmacy onboarding.

If Abrilada isn't working out for your situation, consider exploring alternatives to Abrilada that may be easier to access through your insurance.

How to Find Abrilada in Stock

If you need Abrilada specifically, here are the best ways to find it:

1. Use Medfinder. Visit medfinder.com to check real-time availability at specialty pharmacies near you.
2. Call Pfizer enCompass. Dial 1-844-722-6672 for help locating a pharmacy with Abrilada in stock.
3. Contact your insurer. Ask which specialty pharmacies are in-network and specifically carry Abrilada.
4. Request early refills. Start the refill process at least 7 to 10 days before your next dose to allow time for processing and shipping.

For more detailed tips, read our guide on how to find Abrilada in stock near you.

Final Thoughts

While Abrilada is not in a formal shortage, the realities of specialty pharmacy distribution and insurance coverage can make it feel that way. The key is to be proactive: use tools like Medfinder, work with your specialty pharmacy, and take advantage of manufacturer support programs.

If you're having persistent trouble, don't hesitate to ask your doctor about switching to another interchangeable biosimilar. The most important thing is that you stay on your treatment without gaps. For more information, explore our articles on Abrilada side effects and finding a doctor who prescribes Abrilada.